Influence of vascular endothelial growth factor single nucleotide polymorphisms on non-small cell lung cancer tumor angiogenesis

Oncology Reports

Volumn 29, Issue 1, 2013, Pages 39-44

  Maeda, Ai ^a   Nakata, Masao ^a   Yasuda, Koichiro ^a   Yukawa, Takuro ^a   Saisho, Shinsuke ^a   Okita, Riki ^a   Hirami, Yuji ^a   Shimizu, Katsuhiko ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Angiogenesis; Delta like ligand 4; Polymorphisms; Vascular endothelial growth factor

Indexed keywords

DELTA LIKE LIGAND 4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VASCULARIZATION; VEGF GENE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84872867440     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2075     Document Type: Article

References (29)

1. Yuan A, Yu CJ, Chen WJ, Lin FY, Kuo SH, Luh KT and Yang PC: Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer 89: 475-483, 2000.
2. Han H, Silverman JF, Santucci TS, et al: Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 8: 72-79, 2001.
3. Kaya A, Ciledag A, Gulbay BE, et al: The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med 98: 632-636, 2004.
4. Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, Venitz J and Figg WD: The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 8: 2496-2508, 2009.
5. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V and Hutchinson IV: Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 60: 1245-1249, 1999.
6. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC and Abraham JA: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266: 11947-11954, 1991.
7. Stevens A, Soden J, Brenchely PE, Ralph S and Ray DW: Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63: 812-816, 2003.
8. Watson CJ, Webb NJ, Bottomley MJ and Brenchley PE: Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12: 1232-1235, 2000.
9. Lin CC, Wu HC, Tsai FJ, Chen HY and Chen WC: Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer. Urology 62: 374-377, 2003.
10. Ku KT, Wan L, Peng HC, Tsai MH, Tsai CH and Tsai FJ: Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for oral cancer. Oral Oncol 41: 497-502, 2005.
11. Lu H, Shu XO, Cui Y, et al: Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 65: 5015-5019, 2005.
12. Kim JG, Chae YS, Sohn SK, et al: Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res 14: 62-66, 2008.
13. Heist RS, Zhai R, Liu G, et al: VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 26: 856-862, 2008.
14. Zhai R, Liu G, Zhou W, et al: Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer. Clin Cancer Res 14: 612-617, 2008.
15. Masago K, Fujita S, Kim YH, et al: Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer. Cancer Sci 100: 1917-1922, 2009.
16. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2: 795-803, 2002.
17. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD and Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613, 1996.
18. Thurston G, Noguera-Troise I and Yancopoulos GD: The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer 7: 327-331, 2007.
19. Indraccolo S, Minuzzo S, Masiero M, et al: Cross-talk between tumor and endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancy. Cancer Res 69: 1314-1323, 2009.
20. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW and Harris AL: Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 65: 8690-8697, 2005.
21. Hainaud P, Contrerès JO, Villemain A, Liu LX, Plouët J, Tobelem G and Dupuy E: The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Cancer Res 66: 8501-8510, 2006.
22. Patel NS, Dobbie MS, Rochester M, Steers G, Poulsom R, Le Monnier K, Cranston DW, Li JL and Harris AL: Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res 12: 4836-4844, 2006.
23. Fontanini G, Vignati S, Boldrini L, et al: Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 3: 861-865, 1997.
24. Giatromanolaki A, Koukourakis MI, Sivridis E, et al: Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 85: 881-890, 2001.
25. Martinez JC, Müller MM, Turley H, et al: Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology 54: 598-606, 2009.
26. Donnem T, Andersen S, Al-Shibli K, Al-Saad S, Busund LT and Bremnes RM: Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Cancer 116: 5676-5685, 2010.
27. Tzanakis N, Gazouli M, Rallis G, et al: Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol 94: 624-630, 2006.
28. Hefler LA, Mustea A, Könsgen D, et al: Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res 13: 898-901, 2007
29. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E and Sivridis E: VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46: 293-298, 2004.